# Kailera Therapeutics, Inc. (KLRA)

> Source: Nexqual · https://nexqual.com/KLRA · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Kailera Therapeutics, Inc. (KLRA), nexqual.com/KLRA" · informational, not investment advice.

**Price:** USD 13.27 (+2.71% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 12.92 · day 12.56–13.34 · 52w 9.76–28.23 · market cap $1.72B · NMS

## Key facts
- Insider open-market purchases, last ~7 months: 5 Form 4 filings, $327M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.83 on a 1–5 scale) (6 analysts), mean target USD 42.4 (range 30–57).
- Total return with dividends: 1Y -49.0% vs S&P 500 +14.9%; 5Y -49.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD -1.01, revenue estimate $0K.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 1.5x · Earnings yield -13.78%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
5 purchases, $327M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-04-20 | Rtw Investments, Lp |  | 500,000 | $8.0M | 16 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-20 | Bain Capital Investors Llc |  | 8,398,438 | $134M | 16 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-20 | Koppel Adam | Director | 1,562,500 | $25.0M | 16 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-20 | Bain Capital Life Sciences Investors, Llc |  | 1,562,500 | $25.0M | 16 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-20 | Kaplan Andrew T. | Director | 8,398,438 | $134M | 16 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.83 on a 1–5 scale), 6 analysts; mean target USD 42.4 (low 30, high 57).

## Total return (dividends reinvested)
|  | 1Y (from 2026-04-17) | 5Y (from 2026-04-13) |
|---|---|---|
| Total return | -49.0% | -49.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | — | — |
| Volatility (annualized) | 73.3% | 64.7% |
| Max drawdown | -61.5% (Apr 2026→Oct 2026) | -60.0% (Apr 2026→Sep 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/KLRA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-12)

- "Data are anticipated in 2028. • Phase 2b high-dose clinical trial in obesity fully enrolled: The Phase 2b trial (NCT07458269) enrolled 264 participants in the U.S. with a BMI of 35 or greater with no type 2 diabetes (T2D)."
- "The trial is expected to enroll approximately 320 adult participants with a BMI of 30 or greater, or a BMI of 27 or greater with at least one co-morbidity, which may include T2D."
- "The trial initiated in April 2026, with data expected in 2027. • Positive topline data from two Hengrui Pharma Phase 3 trials in obesity/overweight and T2D: In Hengrui's Phase 3 trial in adults with obesity (HARBOR-1, NCT06904105), participants taking HRS-7535 180 mg achieved a mean weight loss of up to 11.1% from baseline at Week 50, based on an ad hoc analysis under the efficacy estimand 3 ."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.01 | $-0.93 | +9.2% | $0 | 5 |
| Next quarter (ends 2026-12-31) | $-1.16 | $-1.06 | +9.6% | $0 | 5 |
| Current fiscal year (ends 2026-12-31) | $-4.10 | $-3.97 | +3.2% | $0 | 5 |
| Next fiscal year (ends 2027-12-31) | $-4.30 | $-4.10 | +4.9% | $0 | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-04): ±25.2%; last 2 reports averaged ±4.2%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 169.4% | ±25.2% |